Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant
Por um escritor misterioso
Descrição
Immune Checkpoint Blockade for Prostate Cancer: Niche Role or Next Breakthrough?
ASCO GU 2019: Initial Results from a Phase II Study of Nivolumab plus Ipilimumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer - CheckMate 650
Ipilimumab - Wikipedia
ASCO GU 2019: Initial Results from a Phase II Study of Nivolumab plus Ipilimumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer - CheckMate 650
IJMS, Free Full-Text
ASCO GU 2019: Initial Results from a Phase II Study of Nivolumab plus Ipilimumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer - CheckMate 650
Cancers, Free Full-Text
Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors
Avelumab Combined with Stereotactic Ablative Body Radiotherapy in Metastatic Castration-Resistant Prostate Cancer: The Phase 2 ICE-PAC Clinical Trial - Beyond the Abstract
Castration-resistant prostate cancer: latest evidence and therapeutic implications - Daniel L. Suzman, Emmanuel S. Antonarakis, 2014
Cancers, Free Full-Text
Nivolumab: targeting PD-1 to bolster antitumor immunity
Cancers, Free Full-Text
de
por adulto (o preço varia de acordo com o tamanho do grupo)
